Evidence map›Paper›PMID 39046590›Full record

ArticlePituitary2024

Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence.

Anthony Tang, Hussein M Abdallah, Yue-Fang Chang, Georgios A Zenonos, Paul A Gardner, Garret W Choby, Eric W Wang, Carl H Snyderman

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anthony TangSchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Hussein M AbdallahDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Yue-Fang ChangDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Georgios A ZenonosDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Paul A GardnerDepartment of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Garret W ChobyDepartment of Otolaryngology, Center for Skull Base Surgery, University of Pittsburgh, UPMC Presbyterian, 203 Lothrop Street, EEI Suite 500, Pittsburgh, PA, 15213, USA.
Eric W WangDepartment of Otolaryngology, Center for Skull Base Surgery, University of Pittsburgh, UPMC Presbyterian, 203 Lothrop Street, EEI Suite 500, Pittsburgh, PA, 15213, USA.
Carl H SnydermanDepartment of Otolaryngology, Center for Skull Base Surgery, University of Pittsburgh, UPMC Presbyterian, 203 Lothrop Street, EEI Suite 500, Pittsburgh, PA, 15213, USA. snydermanch@upmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe COVID-19 pandemic caused significant disruption to the surgical care of patients. The aim of this study was to analyze the impact of the pandemic on endoscopic endonasal surgery (EES) for patients with a pituitary adenoma.

methodsPatients from 2015 to 2022 that had EES for a pituitary adenoma were included in this study. Patients were separated into pre-COVID (January 2015-March 2020) and COVID (March 2020-September 2022) groups. Univariate analysis was done using chi-square, fisher exact tests, and t-tests to compare groups.

resultsThis study included 492 patients that had EES for their pituitary adenoma. There were 314 patients in the pre-COVID group and 178 patients in the COVID group. Patients in the COVID group had a higher risk analysis index (RAI) frailty score (15 ± 10 pre-COVID vs. 20 ± 9 COVID, P < 0.001) and a higher American Society of Anesthesiology (ASA) physical status score (3 or 4) (72.0% pre-COVID vs. 81.9% COVID, P = 0.02). There were significantly more macroadenoma cases (87.6% pre-COVID vs. 94.4% COVID, P = 0.02) and extrasellar surgical approaches (45.2% pre-COVID vs. 61.2% COVID, P < 0.001) during COVID. There was no significant difference in length of stay (LOS) and readmission rates between groups.

conclusionsPatients that presented during the pandemic tended to be more frail, have more comorbidities, and require additional extrasellar surgical approaches. Despite changes in clinical presentation and operative management, the LOS and readmission rate remained stable during COVID, supporting the safety of this procedure during the recent pandemic.

Indexed as

AdenomaCOVID-19Pituitary NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPandemicsRetrospective StudiesSARS-CoV-2COVID pandemicEndoscopic surgeryPituitary adenoma

Identifiers

PMID39046590

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.